JNJ-64304500

DRUG5 trials

Sponsors

Janssen Research & Development, LLC, Janssen Pharmaceutical K.K.

Conditions

Alopecia AreataCrohn DiseaseHealthy

Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants

CompletedNCT03002025

Janssen Pharmaceutical K.K.Healthy

Start: 2017-01-10End: 2017-09-09Updated: 2025-02-03

A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants

WithdrawnNCT04712006

Janssen Research & Development, LLCHealthy

Start: 2021-05-30End: 2021-10-30Updated: 2021-09-01

Phase 2

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

CompletedNCT02877134

Janssen Research & Development, LLCCrohn Disease

Start: 2016-08-25End: 2022-01-24Updated: 2025-04-29

A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

WithdrawnNCT04655807

Janssen Research & Development, LLCCrohn Disease

Start: 2021-03-03End: 2023-09-04Updated: 2025-04-27

A Study of JNJ-64304500 in Participants With Alopecia Areata

WithdrawnNCT04740970

Janssen Research & Development, LLCAlopecia Areata

Start: 2021-03-24End: 2022-07-20Updated: 2021-05-04

Related Papers

A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn’s Disease

Journal of Crohn s and Colitis2023-03-2010 citations